Press releases

ORYZON reports financial results and corporate update for quarter ended March 31, 2024

ORYZON secures another important patent for its lead CNS asset, vafidemstat

ORYZON announces U.S. FDA clearance of CTEP-CRADA Phase I/II clinical trial sponsored by NCI for iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

ORYZON to provide corporate progress updates at several events in April

ORYZON receives the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation

ORYZON reports financial results and corporate update for quarter ended December 31, 2023

ORYZON to provide corporate progress updates at several events in February-March

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

ORYZON Announces Topline Results from Phase IIb PORTICO study of vafidemstat in Borderline Personality Disorder (BPD)

ORYZON to provide corporate progress updates at several events in January